These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 10531185)

  • 1. Continuous intravenous epoprostenol therapy for pulmonary hypertension in Gaucher's disease.
    Bakst AE; Gaine SP; Rubin LJ
    Chest; 1999 Oct; 116(4):1127-9. PubMed ID: 10531185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IV epoprostenol in Gaucher's disease.
    Elstein D; Zimran A
    Chest; 2000 Jun; 117(6):1821. PubMed ID: 10858430
    [No Abstract]   [Full Text] [Related]  

  • 3. Pulmonary edema complicating continuous intravenous prostacyclin in pulmonary capillary hemangiomatosis.
    Humbert M; Maître S; Capron F; Rain B; Musset D; Simonneau G
    Am J Respir Crit Care Med; 1998 May; 157(5 Pt 1):1681-5. PubMed ID: 9603154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial.
    Badesch DB; Tapson VF; McGoon MD; Brundage BH; Rubin LJ; Wigley FM; Rich S; Barst RJ; Barrett PS; Kral KM; Jöbsis MM; Loyd JE; Murali S; Frost A; Girgis R; Bourge RC; Ralph DD; Elliott CG; Hill NS; Langleben D; Schilz RJ; McLaughlin VV; Robbins IM; Groves BM; Shapiro S; Medsger TA
    Ann Intern Med; 2000 Mar; 132(6):425-34. PubMed ID: 10733441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parenteral and inhaled prostanoid therapy in the treatment of pulmonary arterial hypertension.
    McLaughlin VV; Palevsky HI
    Clin Chest Med; 2013 Dec; 34(4):825-40. PubMed ID: 24267307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transition from IV to subcutaneous prostacyclin: premature withdrawal?
    Shapiro S; Hill NS
    Chest; 2007 Sep; 132(3):741-3. PubMed ID: 17873184
    [No Abstract]   [Full Text] [Related]  

  • 7. [Transition from intravenous to subcutaneous prostacyclin in pulmonary hypertension].
    Escribano Subías P; Cea-Calvo L; Tello de Menesses R; Gómez Sánchez MA; Delgado Jiménez JF; Sáenz de la Calzada C
    Rev Esp Cardiol; 2003 Aug; 56(8):818-21. PubMed ID: 12892628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epoprostenol sodium for treatment of pulmonary arterial hypertension.
    Saito Y; Nakamura K; Akagi S; Sarashina T; Ejiri K; Miura A; Ogawa A; Matsubara H; Ito H
    Vasc Health Risk Manag; 2015; 11():265-70. PubMed ID: 25999730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostacyclin therapy before pulmonary thromboendarterectomy in patients with chronic thromboembolic pulmonary hypertension.
    Nagaya N; Sasaki N; Ando M; Ogino H; Sakamaki F; Kyotani S; Nakanishi N
    Chest; 2003 Feb; 123(2):338-43. PubMed ID: 12576349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infections by gram-negative bacilli in patients with pulmonary arterial hypertension treated with intravenous prostacyclin.
    Gómez Sánchez MA
    Arch Bronconeumol; 2013 Mar; 49(3):128-9. PubMed ID: 23127721
    [No Abstract]   [Full Text] [Related]  

  • 11. Bloodstream infections due to Micrococcus spp and intravenous epoprostenol.
    Valdivia-Arenas MA
    Infect Control Hosp Epidemiol; 2009 Dec; 30(12):1237. PubMed ID: 19888847
    [No Abstract]   [Full Text] [Related]  

  • 12. Continuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension.
    Kuo PC; Johnson LB; Plotkin JS; Howell CD; Bartlett ST; Rubin LJ
    Transplantation; 1997 Feb; 63(4):604-6. PubMed ID: 9047158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension.
    Aguilar RV; Farber HW
    Am J Respir Crit Care Med; 2000 Nov; 162(5):1846-50. PubMed ID: 11069824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prostacyclin and iloprost in aerosol form in severe pulmonary hypertension].
    Olschewski H; Walmrath D; Schermuly R; Ghofrani HA; Grimminger F; Seeger W
    Pneumologie; 1998 Jan; 52(1):3-7. PubMed ID: 9540363
    [No Abstract]   [Full Text] [Related]  

  • 15. Reversal of pulmonary hypertension and subsequent repair of atrial septal defect after treatment with continuous intravenous epoprostenol.
    Frost AE; Quiñones MA; Zoghbi WA; Noon GP
    J Heart Lung Transplant; 2005 Apr; 24(4):501-3. PubMed ID: 15797757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful use of continuous intravenous prostacyclin in a patient with severe portopulmonary hypertension.
    Kähler CM; Graziadei I; Wiedermann CJ; Kneussl MP; Vogel W
    Wien Klin Wochenschr; 2000 Jul; 112(14):637-40. PubMed ID: 11008327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma brain natriuretic peptide as a parameter to assess efficacy of continuous intravenous infusion of prostacyclin (epoprostenol) to treat severe primary pulmonary hypertension: a case report.
    Wakaumi M; Shiga T; Nozaki K; Fujiu K; Shimaya K; Ishizuka N; Matsuda N; Kasanuki H
    Heart Vessels; 2000; 15(3):144-6. PubMed ID: 11289503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transition of stable pediatric patients with pulmonary arterial hypertension from intravenous epoprostenol to intravenous treprostinil.
    Ivy DD; Claussen L; Doran A
    Am J Cardiol; 2007 Mar; 99(5):696-8. PubMed ID: 17317374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Weaning and discontinuation of epoprostenol in children with idiopathic pulmonary arterial hypertension receiving concomitant bosentan.
    Ivy DD; Doran A; Claussen L; Bingaman D; Yetman A
    Am J Cardiol; 2004 Apr; 93(7):943-6. PubMed ID: 15050507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of continuous intravenous epoprostenol therapy on advanced primary pulmonary hypertension in Taiwanese patients.
    Hsu HH; Chen JS; Kuo SH; Chiang FT; Ko WJ; Kuo SW; Huang SC; Lee YC
    J Formos Med Assoc; 2005 Jan; 104(1):60-3. PubMed ID: 15660181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.